rhinitis News
-
Neurent Medical Receives FDA Clearance for NEUROMARK, a Novel Multi-Point Nerve Disruption Treatment for Chronic Rhinitis
GALWAY, Ireland–Neurent Medical, a company pioneering innovative treatments for chronic inflammatory sino-nasal diseases, today announced Food and Drug Administration (FDA) clearance of its proprietary NEUROMARK™ Rhinitis Neurolysis Therapy™ (RNT). The clearance gives clinicians access to an in-office treatment designed to create lesions to disrupt the posterior nasal nerves, ...
-
Neurent Medical Closes $25 Million Series B Funding to Advance Innovative Chronic Rhinitis Treatment
GALWAY, Ireland–(BUSINESS WIRE)–Neurent Medical, a company pioneering innovative treatments for chronic inflammatory sino-nasal diseases, today announced it has closed a $25 million Series B financing. The round was led by new investor LSP, from its LSP HEF-2 fund, and co-led by Atlantic Bridge, investing from its Growth Fund IV. Fountain Healthcare Partners also participated as a ...
-
Neurent raises €9.3m to put paid to chronic runny noses
An Irish company developing a breakthrough therapy for a common nasal condition has raised €9.3 million. Neurent Medical, based in Oranmore, Co Galway, is developing a medical device that would allow doctors treat patients with rhinitis in their offices, rather than in a surgical setting. The funding round was led by Fountain Healthcare Partners, the Irish life sciences fund. Others ...
-
Neurent Medical`s RF-based Minimally Invasive Rhinitis Therapy Earns Acclaim from Frost & Sullivan
Neurent Medical's rhinitis device delivers radio frequency energy in a focused and controllable zone of effect, causing minimal collateral damage to surrounding tissues LONDON, Nov. 13, 2018 /CNW/ -- Based on its recent analysis of the European rhinitis therapy market, Frost & Sullivan recognises Neurent Medical with the 2018 European New Product Innovation Award for developing a ...
-
EU allergy and asthma network marks its achievements
The Global Allergy and Asthma European Network (GA2LEN)1, established in 2005 to facilitate excellence in allergy research across clinical and research institutions in Europe, has recently published a report on its major achievements. Funded by the EU, GA2LEN is composed of a multidisciplinary research network centred on scientific projects in allergy and asthma. It integrates research on ...
-
Pollen Allergies, Hay Fever & IAQ Discussed in New Online Video
Today, the IAQ Video Network and Cochrane & Associates announced the release of another online video to help educate the public about issues that may impact their health. The latest educational video discusses pollen allergies, hay fever and IAQ. Allergic rhinitis is an allergic inflammation of the nasal airways that occurs when an allergen, such as pollen, is inhaled by an individual ...
-
Infrared Coagulation of The Inferior Turbinate: A new treatment for refractory chronic rhinitis
Nasal obstruction remains a challenge to the modem day rhinologist. In the evolving climate of "cost containment" and "risk-outcome analyses", office-based inferior turbinate reduction has regained popularity. This article describes a new method to reduce nasal obstruction in patients with chronic rhinitis when conventional medical therapy has failed. Rhinitis is chronic (CR) when symptoms of ...
-
Neurent Medical Expands Leadership Team to Support Advancement of In-Office Chronic Rhinitis Treatment
GALWAY, Ireland–(BUSINESS WIRE)–Neurent Medical, a company pioneering innovative treatments for chronic inflammatory sino-nasal diseases, today announced expansions of its leadership team. The hires bring deep medical device industry and ear, nose and throat-specific experience to the company that will support commercial advancement of Neurent’s proprietary NEUROMARK™ ...
-
Allergy or air pollution
To give the trees their due, they do an excellent job at pollination, along with their bee helpers of course! However high pollen levels mixed with air pollutants is a key factor in the rise of allergic diseases such as allergic rhinitis and other health problems like asthma. Pollution, particularly from gases like carbon monoxide, nitrogen oxide and nitrogen dioxide typically from car exhaust ...
-
HAL Allergy first company to achieve marketing authorisations in line with Therapieallergene-Verordnung (TAV) in Germany
HAL Allergy B.V. today announced the registration of SUBLIVAC® Birch 40.000 AUN/ml and SUBLIVAC® Trees 40.000 AUN/ml in Germany. These are the first marketing authorisations granted by the Paul Ehrlich Institute following the German Therapieallergene-Verordnung (TAV). The TAV was initiated by the German Federal Ministry of Health on 14 November, 2008, and regulates the marketing ...
-
Understanding the Difference between COVID-19 Symptoms and Sinus Disease World Sinus Health Awareness Day 2021
The American Academy of Otolaryngology–Head and Neck Surgery (AAO-HNS), in partnership with Intersect ENT, Inc., launched a public education campaign that provides clinically-developed information by experts in the field aimed at helping people better understand their nasal and sinus symptoms. World Sinus Health Awareness Day, with its inaugural celebration on September 29, has an ...
-
Pollen, Mold and Other Indoor Contaminants Impact Puerto Rico’s Allergy and Asthma Rates
Allergy and asthma rates in Puerto Rico are much higher than most other parts of the United States. There are a number of factors for why this is likely the case, including the region’s tropical climate which is conducive for the growth of mold and year-round pollen. Flowering plants, trees and grasses release pollen into the environment. The fine powdery substance can be carried by the ...
-
AOBiome Doses First Patient in Phase 1b Clinical Trial of B244 for the Treatment of Pediatric Atopic Dermatitis
AOBiome Therapeutics, Inc. (“AOBiome”), a leading clinical-stage microbiome company focusing on the research and development of therapeutics for dermatological conditions, migraine, hypertension and other systemic diseases, today announced the administering of its lead product candidate, B244, to the first patient in the Company’s Phase 1b clinical trial to treat pediatric ...
-
Hidden Allergens in Christmas meals
This Christmas season, when families gather together and consume tasty holiday foods, it is essential to be aware of allergic reactions, which usually increase during this period. Food allergies are estimated to affect 1% to 10% of adults and children in developed countries[1]. Notably, young children, especially toddlers, are at a higher risk of the potential for an anaphylactic shock due to ...
-
AOBiome Therapeutics Expands Intellectual Property Estate with Issuance of U.S. Patent for Use of Ammonia Oxidizing Bacteria (AOB) for the Treatment of Eczema
AOBiome Therapeutics, Inc. (“AOBiome”), a leading clinical-stage microbiome company focusing on the research and development of a novel class of drugs for inflammatory conditions, central nervous system disorders, and other systemic diseases, today announced that the United States Patent and Trademark Office (USPTO) has issued a patent covering the use of the Company’s Ammonia ...
-
Restore Health Selected To Provide Innovative Allergy Toothpaste System: Allerdent
Allovate, LLC, has signed an agreement with Restore Health, a company specializing in personalized medicine, for the exclusive rights to provide Allerdent™, a new personalized therapeutic toothpaste system for people suffering from allergic rhinitis. Allerdent™ is designed for daily use as part of a normal tooth-brushing regimen and enables allergy sufferers to incorporate ...
-
AOBiome Therapeutics Announces Appointment of Dr. Judith Ng Cashin as Chief Medical Officer
AOBiome Therapeutics, Inc. ("AOBiome"), a leading clinical-stage microbiome company focusing on the research and development of a novel class of drugs for inflammatory conditions, central nervous system disorders, and other systemic diseases, today announced that Dr. Judith Ng Cashin, M.D., has joined the company as Chief Medical Officer effective as of October 1, 2018. "Dr. Ng Cashin has ...
-
Allovate Therapeutics Provides Free Allerdent To Physicians
Allovate Therapeutics, a New York-based biotechnology company, announced today that it is making its allergy immunotherapy delivery platform available without charge to allergy professionals facing difficulties bringing their patients into the office for injections. Allovate was founded in 2012 with the goal of improving and advancing the administration of allergy immunotherapy for patients of ...
-
Allovate Therapeutics Appoints Bob Pomrenke as CEO
Allovate Therapeutics (“Allovate®”), a New York-based biotechnology company focused on improving treatment for allergies, is pleased to announce the appointment of Robert "Bob" Pomrenke to the position of Chief Executive Officer, effective April 1, 2019. Mr. Pomrenke brings over 25 years of sales, marketing and business development experience in the allergy immunotherapy market. ...
-
Altamira Therapeutics and Avernus Pharma Collaborate for Marketing and Distribution of Bentrio in Gulf Countries
HAMILTON, BERMUDA / ACCESSWIRE / February 7, 2022 / Altamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, announced today that it has entered into an agreement for the marketing and distribution of Bentrio™ (the "Agreement"), its nasal spray for protection against airborne viruses and allergens, with Avernus ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you